HK40081099A - Universal formulation - Google Patents

Description

Universal formulations

The present invention relates to a composition comprising at least one quaternary ammonium compound, at least one alcohol ethoxylate and at least one preservative/slow-acting biocide, a wet-wipe comprising a substrate which has been impregnated with said composition, and the use of said composition or said wet-wipe for disinfecting a surface.

In the medical environment there are a wide variety of surfaces, equipment and devices that must not only remain clean, but must also look clean and not carry residues that aesthetically or functionally affect their role in patient care or cross-infection control. Typically, such articles are made of stainless steel, other metals, glass, and/or various plastics and rubbers. They may include screens, keyboards, trays, wheelchairs, carts, walls, windows and many different medical devices and device holders, bed frames, mattresses, toilet bowls and furniture.

With the development of the infection control market, there is an increasing demand for broad spectrum products, which should include the availability of more resistant microorganisms to non-enveloped viruses and mycobacteria. These organisms are highly infectious pathogens that can cause significant medically relevant infections.

Non-enveloped viruses are a challenge for disinfection due to structural differences in capsid core, availability and number of targets, and accessibility of nucleic acids.

The mycobacteria have an outer layer that makes them resistant to commercially available disinfectants. Gamma health limited (Gama Healthcare) seeks to develop powerful product formulations to eliminate surface virucidal and tuberculocidal infections in medical environments.

Biofilms are increasingly widely recognized as a significant medical challenge. It is believed that biofilms may contribute to the continued survival and spread of organisms from one surface to another, thereby becoming a pathway of infection. Biofilms are particularly difficult to eradicate due to the adhesion and protective Extracellular Polymeric Substance (EPS) covering and protecting the organism matrix. Biocides are difficult to penetrate EPS and have an effect on organisms, and furthermore, organisms in biofilms metabolize slower, thereby reducing biocide uptake. Thus, biofilm performance is also a key area of concern throughout the development process (Maillard, JY and McBain, A.2019; Ledwoch, K et al, 2019).

Wet wipes consisting of a substrate impregnated with a disinfecting composition have been on the market for many years and provide simple and effective infection control solutions for healthcare services and other fields.

Although the wet wipes have broad antimicrobial capabilities, their performance against adenovirus and Mycobacterium geotrichum and their activity against biofilms during short contact times are still enhanced.

It is an object of the present invention to provide a composition that is effective in a medical environment for a short, reasonable and comparable contact time, especially with increased activity against viruses and mycobacteria for the short contact times associated with hospital sterilization.

This object is solved by a composition comprising at least one quaternary ammonium compound, at least one alcohol ethoxylate and at least one preservative and/or slower acting biocide, in a mode of action different from QAC (used herein to refer to preservatives only).

The composition is based on a combination of a quaternary ammonium compound, a preservative and a surfactant alcohol ethoxylate. The compositions successfully combined cationic and anionic ingredients that were previously thought to deactivate when combined, thus preventing activity against microorganisms, but this was not the case. In contrast, this particular combination enables a prolonged action on viruses and mycobacteria within the relatively short contact time required for hospital disinfection.

The composition provides a range of antimicrobial activities, including virucidal, mycobacterial and biofilm activities, which current wet wipes comprising a substrate impregnated with a disinfecting composition do not.

The addition of alcohol ethoxylates and preservatives alters the performance of such products over known formulations.

The compositions of the present invention have been developed to enable viruses that are more difficult to kill (e.g., non-enveloped viruses and mycobacteria) to be killed and the biofilm eradicated.

The composition comprises at least one quaternary ammonium compound (QUAT). Quaternary ammonium compounds are the most commonly used antimicrobial agents in medical environments and in external disinfectant products because of their broad antimicrobial efficacy. The quaternary ammonium salt has cation, and can combine with gram-negative organism cell membrane or gram-positive organism cell wall anion component, and aggregate and dissolve hydrophobic component. This can lead to widespread damage and leakage of cell contents, leading to cell death (Sharma, N et al, 2017).

Furthermore, QUAT interferes with intracellular processes, enzymatic activity or the DNA/RNA replication cycle, and therefore, QUAT-containing products are active against gram-positive and gram-negative bacteria, enveloped viruses and limited fungi and mycobacteria.

The composition comprises at least one preservative. A preservative is a substance or chemical used to prevent microbial growth or decomposition by undesirable chemical changes. The preservative is preferably an antimicrobial preservative to prevent bacterial degradation.

The composition comprises at least one alcohol ethoxylate. Alcohol ethoxylates are a group of nonionic surfactants which are obtained by alkoxylation by reacting ethylene oxide, propylene oxide or butylene oxide, preferably ethylene oxide, with primary long-chain fatty or oxo alcohols in the presence of basic or acidic catalysts at temperatures of 120-200 ℃ and pressures of 1-10 bar.

In a typical application, the alcohol is converted to the general formula R (OC) ₂ H ₄ ) _n A compound of OH, wherein n ranges from 1 to 22.

Preferably, the at least one alcohol ethoxylate is of the formula R (OC) ₂ H ₄ ) _n Compounds of OH, wherein n ranges from C ₆ To C ₂₂ . Primary, secondary or tertiary alcohol ethoxylates can be used. Preferably, n ranges from C ₉ To C ₁₁ 。

Typically, alcohol ethoxylates possess multifunctional properties including soil release, foaming, coagulant aids, and surface tension reduction. The addition of alcohol ethoxylates may improve the solubility of fats and proteins, which may contribute to microbial activity.

The composition according to the invention is preferably characterized in that the at least one alcohol ethoxylate comprises at least one primary alcohol ethoxylate.

Primary alcohol ethoxylates are the above-mentioned alcohol ethoxylates, wherein the alcohol moiety is a primary alcohol.

Particularly preferred alcohol ethoxylates include Neodol, Marlipal, Exxal, Libranone from Monarch Chemicals, Rocara and other manufacturers and suppliers. Such other alcohol ethoxylates can be used, for example, in secondary and tertiary alcohol ethoxylates.

The composition of the invention is preferably characterized in that the at least one preservative comprises 2-phenylphenol, phenoxyethanol, phenylethyl alcohol, tocopherol, 2-bromo-2-nitro-1, 3-propanediol, amidines (including bisamidine, propiamidine, etc.), iodohexamidine, parabens, benzyl alcohol and its containing substituents, isothiazolinones such as methylisothiazolinone and methylchloroisothiazolinone, IBPC and/or others including parabens and phenols.

The composition according to the invention is preferably characterized in that the at least one quaternary ammonium compound comprises benzalkonium chloride, didecyldimethylammonium chloride, PHMB and/or CHG.

The composition according to the invention is preferably characterized in that the at least one quaternary ammonium compound is present in an amount of 0.2% to 1.0% w/v, preferably in an amount of 0.3% to 0.7% w/v.

The composition according to the invention is preferably characterized in that the at least one alcohol ethoxylate is present in an amount of 0.1% to 10% w/v, preferably in an amount of 0.3% to 3.0% w/v.

The composition according to the invention is preferably characterized in that the at least one preservative is present in an amount of 0.02% to 2.0% w/v, preferably in an amount of 0.02% to 1.0% w/v.

The composition according to the invention is preferably characterized in that it further comprises at least one polyoxypropylene/polyoxyethylene block copolymer.

Preferably, the block copolymer comprises different units of polyoxyethylene (polypropylene oxide) and polyoxyethylene (polyethylene oxide). Such block copolymers increase the solubility of the hydrophobic material.

Suitable polyoxypropylene/polyoxyethylene block copolymers include poloxamer 184, poloxamer 181, poloxamer 182, poloxamer 183, poloxamer 185, poloxamer 188, poloxamer 101, poloxamer 105, poloxamer 108, poloxamer 123, poloxamer 212, poloxamer 217, poloxamer 234, poloxamer 235, poloxamer 333, poloxamer 335, poloxamer 401, poloxamer 403, and/or poloxamer 407.

The composition according to the invention is preferably characterized in that the composition further comprises propylene-1, 2-diol glycerol, panthenol and/or allantoin, preferably in an amount of 0.01 to 1.0% w/v, preferably in an amount of 0.1 to 0.8% w/v. The addition of propane-1, 2-diol has the advantage of being helpful for dermal application. More complex emollients and skin conditioning agents, such as aloe vera and/or vitamin E, may be used.

The composition according to the invention is preferably characterized in that the composition further comprises 2-phenoxyethanol, preferably in an amount of 0.05 to 1% w/v, preferably in an amount of 0.2 to 0.8% w/v. The advantage of adding 2-phenoxyethanol includes that it will act as a slower acting biocide.

The composition according to the invention is preferably characterized in that the composition further comprises anhydrous 2-hydroxypropane-1, 2, 3-tricarboxylic acid, preferably in an amount of 0.001 to 10.0% w/v, preferably in an amount of 0.001 to 5.0% w/v. An acid such as anhydrous 2-hydroxypropane-1, 2, 3-tricarboxylic acid is added as a buffer.

The composition according to the invention is preferably characterized in that the composition further comprises trisodium citrate dihydrate, preferably in an amount of 0.001 to 10.0% w/v, preferably in an amount of 0.001 to 5.0% w/v. An acid such as trisodium citrate dihydrate is added as a buffer.

The composition according to the invention is preferably characterized in that it further comprises one or more additives selected from the group consisting of: one or more disinfectants, stabilizers, preservatives, chelates, metals, natural oils, dyes, fragrances, odor masking agents, and/or mixtures thereof.

Each of these additives is preferably present in an amount of 0.001 to 2.0% w/v, preferably 0.001 to 1.50% w/v.

The composition according to the invention is preferably characterized in that it is in the form of an aqueous or hydroalcoholic solution or dispersion.

The aqueous alcohol solution or dispersion preferably comprises a mixture of 80% water and 20% alcohol.

Preferred alcohols include ethanol, propan-2-ol, propan-1-ol and/or 3-butoxypropan-2-ol.

The composition according to the invention is preferably characterized in that it comprises:

from 0.3% to 3.0% (w/v) of a primary alcohol ethoxylate,

from 0.02% to 3.0% (w/v) 2-phenylphenol,

from 0.3% to 0.7% (w/v) benzalkonium chloride,

from 0.3% to 0.7% (w/v) didecyl dimethyl ammonium chloride,

from 0.0001% to 0.5% (w/v) of a polyoxypropylene/polyoxyethylene block copolymer, preferably poloxamer 184,

from 0.1% to 0.8% (w/v) propane-1, 2-diol, and

0.2% to 0.8% (w/v) 2-phenoxyethanol

And the solvent is water.

Thus, the polyoxyethylene/polyoxyethylene block copolymer preferably comprises poloxamer 184. The alcohol ethoxylate preferably comprises n is C ₉ -C ₁₁ Primary alcohol ethoxylate of (1).

The composition according to the invention is preferably characterized in that it comprises:

from 0.3% to 3.0% (w/v) of a primary alcohol ethoxylate,

from 0.02% to 3.0% (w/v) 2-phenylphenol,

from 0.3% to 0.7% (w/v) benzalkonium chloride,

from 0.3% to 0.7% (w/v) didecyl dimethyl ammonium chloride,

from 0.0001% to 0.5% (w/v) of a polyoxypropylene/polyoxyethylene block copolymer, preferably poloxamer 184,

0.1% to 0.8% (w/v) propane-1, 2-diol, and

0.2% to 0.8% (w/v) 2-phenoxyethanol,

0.01 to 0.3 percent of essence,

0.001 to 5.0% of anhydrous 2-hydroxypropane-1, 2, 3-tricarboxylic acid,

from 0.001% to 5.0% trisodium citrate dihydrate,

and the solvent is water.

Thus, the polyoxyethylene/polyoxyethylene block copolymer preferably comprises poloxamer 184. The alcohol ethoxylate preferably comprises n is C ₉ -C ₁₁ Primary alcohol ethoxylate of (1).

The composition according to the invention is preferably characterized in that it comprises:

1% w/v of an alcohol ethoxylate,

0.1% (w/v) 2-phenylphenol,

0.54% w/v benzalkonium chloride (50%),

0.54% (w/v) didecyl dimethyl ammonium chloride (80%),

0.12% (w/v) of a polyoxypropylene/polyoxyethylene block copolymer,

0.2% (w/v) propane-1, 2-diol and

0.6% (w/v) 2-phenoxyethanol,

0.05 percent of essence, and is prepared by mixing the following raw materials,

0.03% of anhydrous 2-hydroxypropane-1, 2, 3-tricarboxylic acid,

0.1% trisodium citrate dihydrate,

and the solvent is water.

Thus, the polyoxyethylene/polyoxyethylene block copolymer preferably comprises poloxamer 184. The alcohol ethoxylate preferably comprises n is C ₉ -C ₁₁ Primary alcohol ethoxylate of (1).

The present invention also relates to a wet-wipe comprising a substrate that has been impregnated with the composition as described in the preceding paragraphs.

The substrate impregnated with the composition is preferably a nonwoven material. Suitable nonwoven materials include, but are not limited to, those that do not contain a binder, such that the binder is not adversely affected by the composition, nor does it itself cause soiling. Examples of binderless nonwovens include jet or spunlace nonwovens. However, other types, such as wet laid, air laid, thermal bonded, or stitch bonded types may also be used.

The wipe may comprise fibers made from any one or a mixture of polypropylene, polyester, polyethylene, viscose, cotton, recycled wood pulp and cellulose. They may also include microfiber and nanofiber products.

The substrate is preferably produced in the form of individual paper towels or a roll of perforated material from which individual paper towels are to be separated, wherein the individual paper towels have been impregnated with the composition and packaged ready for dispensing from a resealable jar, pail, flow pack or the like. Alternatively, the impregnated wipe may be individually sealed in a package made from a suitable packaging material, such as an impermeable foil, cellophane, or the like.

The ingredients of the composition of the present invention are simply mixed together to form an aqueous or aqueous-alcoholic solution or dispersion, and the substrate may then be impregnated by soaking it in the composition, thereby producing a wet-wipe in accordance with the present invention.

Such wet wipes are useful for cleaning a variety of surfaces and materials and removing various types and levels of organic and inorganic soils in a manner that leaves the surface clean and disinfected.

The present invention also relates to the use of a composition or wet wipe as described above for disinfecting a surface.

The compositions of the invention were tested according to standard methods to determine the improvement in microbiological efficacy and the improvement in broad spectrum efficacy of the compositions of the invention.

Microbiological efficacy was tested according to the EN standards for bacteria (EN 13727; EN 1656; EN 16615), yeast/fungi (EN 13624; EN 16615; EN 1657), mycobacteria (EN 14348), viruses (EN 14476; ASTME1052) and biofilms. There is no standard method approved for biofilm testing, so the model tested corresponds to that developed and released at the university of Cardiff (K.Ledwoch et al 2019).

For all microbiological tests, the formulations were tested as liquid formulations extracted from the substrate. All tests represent the conditions of use of the product in a medical environment, including contact time, temperature, test organism and interfering substances.

Bactericidal test

EN 13727 and EN 1656:

suspension assays for establishing bactericidal activity are described in detail. The product is added to the bacterial test suspension in the interfering substance solution and maintained at a specific temperature and contact time.

At the end of this contact time, an aliquot is taken; the bactericidal effect was neutralized and the number of surviving bacteria and the reduction were counted. The product should be reduced by at least 5 log10 log orders (lg).

EN 16615

A vehicle test is described in detail for establishing germicidal activity by a wipe on a surface. The test surfaces were lined with 4 5X5cm square marks, the "test areas".

Test area 1 on the test surface is inoculated with a bacterial test suspension in a solution of an interfering substance. The inoculum was dried. The test surface is wiped with the product, starting at the front of the test area 1, turning immediately after the test area 4, and then wiping back to the starting point. Water control tests were performed in parallel: the wipe was wetted with water instead of product.

At the end of the contact time, the test organisms were recovered from each test area with a moistened cotton swab. The swab is placed in a tube containing the broth and the neutralizing agent, and the test organism is separated from the swab by shaking. The number of surviving test organisms in each sample was determined and the reduction calculated.

For bacteria on test area 1, the product should demonstrate a reduction in counts by at least 5 log10 log (lg). The CFU average for test zones 2 to 4 should be equal to or less than 50 and the CFU average for the water control should be equal to or greater than 10.

Yeast/fungus assay

EN 13624 and EN 1657:

suspension tests for establishing fungicidal or fungicidal activity are described in detail. The product is added to a test suspension of fungi (yeast cells or mould spores) in a solution of interfering substances and is kept at a specific temperature and contact time.

Taking an aliquot at the end of the contact time; the fungicidal action was neutralized and the number of surviving fungi and the reduction were calculated. The product should be reduced by at least 4 log10 log orders (lg).

EN 16615

A vehicle test for establishing a yeast-killing activity by a wipe on a surface is described in detail. The test surfaces are marked with 4 squares of 5x5cm, i.e., "test areas," aligned.

Test area 1 on the test surface is inoculated with a bacterial test suspension in a solution of an interfering substance. The inoculum was dried. The test surface was wiped with product, starting at the front of the test area 1, turning immediately after the test area 4, and then wiped back to the starting point. Water control tests were performed in parallel: the wipe was wetted with water instead of product.

At the end of the contact time, the test organisms were recovered from each test area with a moistened cotton swab. The swab is placed in a tube containing the broth and the neutralizing agent, and the test organism is separated from the swab by shaking. The number of surviving test organisms in each sample was determined and the reduction was calculated.

For bacteria on test area 1, the product should demonstrate a reduction in counts by at least 4 log10 log (lg). The CFU average for test zones 2 to 4 should be equal to or less than 50 and the CFU average for the water control should be equal to or greater than 10.

Mycobacterial assay

EN 14348

Suspension assays for determining mycobacterial activity are described in detail. To the product sample is added a test suspension of mycobacteria in a solution of interfering substance. The mixture was maintained at 20 ℃. + -. 1 ℃ for the selected contact time. Taking an aliquot at the end of the contact time; the mycobacteriacidal and/or mycobacterial inhibitory activity in this fraction is immediately neutralized or inhibited by validated methods.

The number of viable mycobacteria in each sample was determined and the reduction was calculated.

The following two test organisms should be used to assess mycobacterial activity. Mycobacterium avium (Mycobacterium avium) ATCC 15769 and Mycobacterium terreus (Mycobacterium terrae) ATCC 15755. Tuberculocidal activity should be assessed using only M.terreus. The count of products should be reduced by at least 4 log10 log steps (lg).

Virucidal assay

EN 14476

Suspension assays for determining virucidal activity are described in detail. The product sample is added to the virus test suspension in the interfering substance solution. The mixture is maintained at one of the specified conditions of temperature and contact time. Taking an aliquot at the end of the contact time; virucidal effect in this aliquot was immediately inhibited by validated methods (dilution of the sample in ice-cold cell maintenance medium). The dilution is transferred to a cell culture unit (petri dish, test tube or microtiter plate well) using a monolayer or cell suspension. Infectivity testing can be performed by plaque testing or quantum testing.

After incubation, according to the Spearman-kappa method (Spearman and)) Or infectious titer was calculated by plaque counting. The reduction in viral infectivity was calculated from the difference in lg viral titer between before and after product treatment. The product should demonstrate a reduction in viral titer of at least 4 log10 log (lg).

ASTME1052

The test method is intended to determine whether the test substance is capable of inactivating the virus in suspension.

1 part virus was added to 9 parts of the test product, and after the study contact time was complete, the test and recovery suspensions were neutralized. The neutralized test, recovery, cytotoxicity control and neutralized control suspensions were serially diluted in the appropriate medium. Each dilution was plated onto a host cell monolayer in quadruplicate in 24-well trays. Media was added to each well and the host cell-virus system was allowed to incubate for the appropriate time.

At the end of the incubation time, the assay was scored using standard cell culture methods.

Each well in the tray was examined under a microscope for the presence of an infected cytopathic effect (CPE). The cytotoxic control wells were examined for damage caused by the test product.

The spearman-kappa method or other appropriate statistical method is used to quantify the number of infectious viruses present in the assay. The product should demonstrate a reduction in viral titer of at least 4 log10 log (lg).

Biofilm assay

Dry biofilm model

The bacteria are initially cultured under normal aqueous conditions to allow initial adhesion and biofilm formation. Followed by a cycle of drying and hydration phases for a total duration of 12 days. The reduction in bacterial viability (Log 10 reduction per ml CFU) gives the number of bacteria removed or killed after wiping. The Log10 reduction was calculated based on the difference between the number of bacteria recovered in the untreated (control) and treated samples.

The transfer test was aimed at studying the ability of viable bacteria to transfer in the dried surface biofilm after wiping. Positive growth/inhibition was recorded and transferability was calculated as the number of positive contacts/inhibition.

Regrowth measures the time required for the DSB to recover after treatment. The days were recorded when the color of the DE broth indicating bacterial growth changed from purple to yellow.

The following non-limiting examples further illustrate the invention.

Example (b):

the compositions of table 1 were prepared by mixing the listed ingredients in water.

Table 1:

table 2:

table 3:

table 4:

table 5:

table 6:

microbiological efficacy was tested as described previously according to the EN standards for bacteria (EN 13727; EN 1656; EN 16615), yeast/fungi (EN 13624; EN 16615; EN 1657), mycobacteria (EN 14348), viruses (EN 14476; ASTME1052) and biofilms.

The results are summarized in table 7.

Table 7:

the compositions comprising quaternary ammonium salts in combination with primary alcohol ethoxylates and 2-phenylphenol clearly show a significant improvement in virucidal and mycobacterial antimicrobial efficacy and possess biofilm activity.

Microbiological efficacy data clearly indicate that the composition has a short contact time and is effective (relevant) under the actual medical conditions used, and all tests are performed under clinically dirty conditions.

The composition has a broader spectrum of efficacy compared to known formulations, which was not possible until the composition was discovered. It has been shown to improve the activity of non-enveloped viruses associated with a medical environment (e.g., adenoviruses and noroviruses) within a 30 second contact time. This is important because hospital surfaces typically dry for 2-5 minutes.

In addition, the composition can kill mycobacteria, especially Mycobacterium terrae, and has tuberculocidal effect. This level of activity is also considered to be difficult to achieve since the waxy outer coating is difficult to break down quickly to exert a biocidal effect. The composition achieves this in a relatively short contact time of 10 seconds.

Furthermore, as is clear from table 2, the formulation has excellent biofilm activity. The clearance rate of the staphylococcus aureus and the candida aureus is respectively more than 7 log grades and 6 log grades. In addition, it has a low transfer rate to the surface and a long regeneration time. These results are superior to well known formulations.

Overall, a significant improvement in efficacy of the composition can clearly be seen. The compositions, in addition to having significant biofilm activity, are capable of achieving prolonged and improved efficacy against non-enveloped viruses, adenoviruses and mycobacteria.

Reference to the literature

ASTM E1052-11, Standard Test Method for assessing microbicidal Activity on Viruses in Suspension (Standard Test Method to Association of the Activity of microorganisms against Viruses in Suspension in Suspension), ASTM International Association (ASTM International), West Conshouse Hokken, Pa., 2011,www.astm.org.

BS EN 13727:3012+ A2:2015 Quantitative suspension Test for evaluation of bactericidal activity in Chemical disinfectants and antiseptics-medical field-Test methods and requirements (stage 2, step 1). BSI Standard publication.

BS EN 1656:2009. "Quantitative suspension Test of Chemical disinfectants and antiseptics and requirements for assessment of bactericidal activity of Chemical disinfectants and antiseptics used in the veterinary medicine field-Test methods and requirements (stage 2, step 1) (" Chemical disinfectants and antiseptics Quantitative suspension Test for the evaluation of bacterial activity of Chemical disinfectants and antiseptics use in the scientific area-Test methods and requirements (phase 2, step 1)). BSI standard publication.

BS EN 16615:2015 Quantitative Test method for mechanical action of Wet wipes on non-porous surfaces for Chemical disinfectants and antiseptics-Test method and requirements for Sterilization and Yeast Activity assessment (4-field Test) -Test method and requirements (stage 2, step 2) (Chemical diagnostics and antimicrobial-Quantitative Test method for the evaluation of bacterial and biological activity on non-porous surfaces) BSI Standard publication (4-field Test) -Test methods and requirements (phase 2, step 2)).

BS EN 13624:2013, Quantitative suspension Test for evaluation of fungicidal or fungicidal Activity in the medical field- -Test methods and requirements (stage 2, step 1), BSI Standard publication.

BS EN 1657:2016 Quantitative suspension Test for evaluation of fungicidal or yeast-killing activity of Chemical disinfectants and antiseptics- -Chemical disinfectants or antiseptics used in veterinary medicine- -Test methods and requirements (stage 2, step 1) - -published by BSI Standard (Chemical disinfectants and antiseptics- -Quantitative determination Test for the evaluation of Chemical disinfectants and antiseptics activity of Chemical disinfectants and antiseptics in the field of veterinary medicine- -BSI Standard.

BS EN 14348:2005 Quantitative suspension Test for mycobacterial Activity assessment of Chemical disinfectants including Instrument disinfectants in the field of Chemical disinfectants and antiseptics- -Test methods and requirements (stage 2, step 1). BSI Standard publication.

BS EN 14476:2013+ A1:2015 (Quantitative suspension Test for evaluation of virucidal activity in the medical field- -Test methods and requirements (stage 2/Step 1)) BSI Standard publication.

Ledwoch.K., Said, J., Norville, P and Maillard, J.Y.2019, "Artificial drying surface Biofilm models for testing the effectiveness of cleaning and disinfecting" (R) surface biological models for testing the effectiveness of cleaning and disinfecting "(" R ". E.). E.N. Applied microbiology.68, 329-336.

Maillard JY and McBain a.2019, "biofilms and their control in medical care environments (Biofilm in healthcare settings and their control),. Lett Appl microbiol.2019, month 4; 68(4):268.

Sharma, n., Aron, n., and Kumar, a.2017. "eye infection: prevention and Management of "Ocular Infections: prophyxiases and Management", Jaypee.

Claims (15)

1. A composition comprising at least one quaternary ammonium compound, at least one alcohol ethoxylate, and at least one preservative.

2. The composition of claim 1, wherein the at least one alcohol ethoxylate comprises at least one primary alcohol ethoxylate.

3. The composition of any one of claims 1 or 2, wherein the at least one preservative comprises 2-phenylphenol.

4. The composition of any one of claims 1 or 3, wherein the at least one quaternary ammonium compound comprises benzalkonium chloride and/or didecyldimethylammonium chloride.

5. The composition of any of claims 1 or 4, wherein the at least one quaternary ammonium compound is present in an amount of 0.2% to 1% w/v.

6. A composition according to any one of claims 1 or 5 wherein the at least one primary alcohol ethoxylate is present in an amount of from 0.1% to 10% w/v.

7. The composition of any one of claims 1 or 6, wherein at least one preservative is present in an amount of 0.02 to 2% w/v.

8. The composition of any of claims 1 or 7, wherein the composition further comprises at least one polyoxypropylene/polyoxyethylene block copolymer.

9. The composition of any one of claims 1 or 8, wherein the composition further comprises one or more additives selected from the group consisting of: one or more disinfecting agents, stabilizing agents, preservatives, dyes, fragrances, odor masking agents and/or mixtures thereof.

10. The composition of any one of claims 1 or 9 in the form of an aqueous or aqueous alcoholic solution or dispersion.

11. The composition of any one of claims 1 or 10, wherein the composition comprises:

from 0.3% to 3.0% (w/v) of a primary alcohol ethoxylate,

from 0.02% to 3.0% (w/v) 2-phenylphenol,

from 0.3% to 0.7% (w/v) benzalkonium chloride,

from 0.3% to 0.7% (w/v) didecyl dimethyl ammonium chloride,

from 0.0001% to 0.5% (w/v) of a polyoxypropylene/polyoxyethylene block copolymer, preferably poloxamer 184,

0.1% to 0.8% (w/v) of propane-1, 2-diol, and

0.2% to 0.8% (w/v) 2-phenoxyethanol

And the solvent is water.

12. A wet-wipe comprising a substrate that has been impregnated with the composition of any of claims 1 to 11.

13. The wet-wipe of claim 12 wherein said substrate comprises fibers made from any one of polypropylene, polyester, polyethylene, viscose, cotton, recycled wood pulp, cellulose, microfibers, and nanofibers, or mixtures thereof.

14. The wet wipe as set forth in any one of claims 12 or 13 wherein the substrate is packaged for ease of dispensing from a tub, drum, flow-through package, or individually sealed packaging machine.

15. Use of a composition according to any one of claims 1 to 11 or a wet wipe according to any one of claims 12 to 14 for disinfecting a surface.